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Summary. In recent years nitric oxide (NO) has 
emerged as a unique biological messenger. NO is a 
highly diffusible gas, synthesized from L-arginine by the 
enzyme nitric oxide synthase (NOS). Three unique 
subtypes of NOS have been described, each with a 
specific distribution profile in the brain and periphery. 
NOS subtype I is present, among other areas, in the 
hippocampus, hypothalamus, pituitary and adrenal 
gland. Together these structures form the limbic- 
hypothalamic-pituitary-adrenal (LHPA) or stress axis, 
activation of which is one of the defining features of a 
stress response. Evidence suggests that NO may 
modulate the release of the stress hormones ACTH and 
corticosterone, and NOS activity and transcription is 
increased in the LHPA axis following various stressful 
stimuli. Furthermore, following activation of the stress 
axis, glucocorticoids are thought to down-regulate the 
transcription and activity of NOS via a feedback 
mechanism. Taken together, current data indicate a role 
for NO in the regulation of the LHPA axis, although at 
present this role is  not well defined. It has been 
suggested that NO may act as a cellular communicator in 
plasticity and development, to facilitate the activation or 
the release of other neurotransmitters, to mediate 
immune responses, andlor as a vasodilator in the 
regulation of blood flow. In the following review we 
summarize some of the latest insights into the function 
of NO, with special attention to its relationship with the 
LHPA axis. 
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Introduction 
For many years indirect donors of nitric oxide (NO), 
such as nitroglycerin, have been used to treat people 
suffering from heart attacks due to their potent 
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vasodilatory effects. In the late eighties, the radical gas 
NO was found to be the diffusible substance causing 
vasodilatation, previously known as "endothelium- 
derived relaxing factor" (EDRF) (Ignarro et al., 1987; 
Palmer et al., 1987). NO has an ultra-short half-life in 
the millisecond range. Upon formation, NO diffuses and 
binds to its targets, the most common of which is the 
heme group of soluble guanyl cyclase (sGC). This 
neurotransmitter is atypical, in that it is not accumulated 
in vesicles, does not require membrane receptors to 
mediate i ts  action and has the capacity to act 
retrogradely, from post- to presynaptic terminals. Since 
the description of NO as a member of a new class of 
neurotransmitter, and its designation as molecule of the 
year by Science in 1992, a vast literature has brought 
insights into its ubiquitous distribution, the enzymes 
responsible for its synthesis and its unique mode of 
action (for review see Wolf, 1997). 
Nitric oxide synthase characteristics 
NO biosynthesis 
Nitric oxide synthase (NOS) utilizes L-arginine and 
O2 as substrates of a reaction that produces L-citrulline 
and the radical gas NO (Fig. 1) (Knowles et al., 1989). 
NOS is  a homodimeric enzyme divided into an 
oxygenase and reductase domain (for review see Stuehr, 
1997). Five electrons from NADPH are transferred in 
sequence to flavin adenine dinucleotide (FAD) and 
flavin mononucleotide (FMN) located in the reductase 
domain (Fig. 2). L-arginine binds to the oxygenase 
domain of NOS and its guanidino group acts as a final 
acceptor of the electrons. Together with O2 the reaction 
forms the intermediate NW-hydroxy-arginine. The 
enzyme also contains binding sites for heme, 
tetrahydrobiopterin (BH4) and calmodulin (CaM), all of 
which are required for NOS to be completely functional. 
A consensus sequence for phosporylation is present, but 
the functional significance of this sequence has yet to be 
demonstrated. 
Thusfar, three subtypes of NOS have been described, 
termed subtypes I, I1 and I11 based on their order of 
cloning. NOS subtypes I, I1 and 111 represent unique 
genes and are localized on chromosomes 12, 17 and 7 









